Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 9, 2009, Pages 3530-3534

  Chillarón, Juan J ^a,b   Goday, Alberto ^a,b   Flores Le Roux, Juana A ^a,b   Benaiges, David ^a   Carrera, María J ^a   Puig, Jaume ^a   Cano Pérez, Juan F ^a   Pedro Botet, Juan ^a,b,c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Department of Medicine ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROANGIOPATHY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 69949107065     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0960     Document Type: Article

References (27)

1. DeFronzo RA, Hendler R, Simonson D 1982 Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes31:795-801 (Pubitemid 12062869)
2. DeFronzo RA, Simonson D, Ferrannini E 1982 Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulindependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23:313-319
3. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti GC 1993 Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883-887 (Pubitemid 23291590)
4. Teupe B, Bergis K 1991 Epidemiological evidence for "double diabetes." Lancet 337:361-362
5. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ 2002 Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease in type 1 diabetes. Metabolism 51:248-254 (Pubitemid 34168241)
6. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ 2003 Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh epidemiology of diabetes complications study. Diabetes Care 26:1374-1379 (Pubitemid 36929165)
7. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferris B, Reboldi P, Michel G, Manes C, Fuller JH; EURODIAB Prospective Complications Study Group 2004 Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 27:530-537 (Pubitemid 38174083)
8. Kilpatrick ES, Rigby AS, Atkin SL 2007 Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 30:707-712
9. Chatuverdi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM; EURODIAB Prospective Complications Study Group 2001 Markers of insulin resistance are strong risk factors for nephropathy incidence in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 24:284-289 (Pubitemid 32119126)
10. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE 2002 Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int 62:963-970
11. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N 2004 Factors associated with progression to macroalbuminuria in microalbuminurictype1diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020-1028 (Pubitemid 38918161)
12. Tesfaye S, Chatuverdi N, Eaton SE, Ward JD, Manes C, Ionescu- Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group 2005 Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341-350
13. de Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, Steffes MW, Weiss NS, Brunzell JD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group 2007 Central obesity, incident microalbuminuria, andchange in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 18:235-243
14. American Diabetes Association 2009 Standards of medical care in diabetes-2009. Diabetes Care 32:S13-S61
15. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ 2000 Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626-632
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Kraiss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735-2752
17. Faber OK, Binder C 1977C-peptide response to glucagon. Atest for the residual β-cell function in diabetes mellitus. Diabetes 26:605-610
18. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW 2004 C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta cell function-Report of an ADA workshop, October 21-22, 2001. Diabetes 53:250-264 (Pubitemid 38044724)
19. Wallace TM, Matthews DR 2002 The assessment of insulin resistance in man. Diabet Med 19:527-534
20. Pambianco G, Costacou T, Orchard TJ 2007 The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30:1248-1254 (Pubitemid 46684655)
21. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K Saraheimo M, Wadén J, Rönnback M, Rosengard- Bärlund M, Bjö rkesten C-G, Taskinen M-R, Groop P-H, on behalf of the FinnDiane Study Group 2005 Metabolic syndrome in type 1 diabetes. Diabetes Care 28:2019-2024
22. Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H 2007 Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 115:495-501 (Pubitemid 350056761)
23. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
24. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-12453
25. González-Clemente JM, Mauricio D, Richart C, Broch M, Caixàs A, Megia A, Giménez-Palop O, Simón I, Martínez-Riquelme A, Giménez- Pérez G, Vendrell J 2005 Diabetic neuropathy is associated with activation of the TNF-α system in subjects with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 63:525-529 (Pubitemid 41626747)
26. González-Clemente JM, Vilardell C, Broch M, Megia A, Caixàs A, Giménez-Palop O, Richard C, Simón I, Martínez-Riquelme A, Arroyo J, Didac M, Vendrell J 2007 Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type1diabetes. Eur J Endocrinol 157:31-38 (Pubitemid 47162563)
27. Cantón A, Fernández Castañer M, Conget I, Carreras G, Castell C, Tresserras R 2004 Type 1 diabetes mellitus in Catalonia: chronic complications and metabolic control ten years after onset. Med Sci Monit 10:CR185-CR190 (Pubitemid 38787627)